RhumbLine Advisers’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.88K | Sell |
2,716
-86,917
| -97% | -$124K | ﹤0.01% | 3941 |
|
|
2025
Q1 | $143K | Sell |
89,633
-10,382
| -10% | -$16.6K | ﹤0.01% | 3277 |
|
|
2024
Q4 | $360K | Buy |
100,015
+4,366
| +5% | +$15.7K | ﹤0.01% | 2878 |
|
|
2024
Q3 | $545K | Buy |
95,649
+5,028
| +6% | +$28.7K | ﹤0.01% | 2646 |
|
|
2024
Q2 | $419K | Buy |
90,621
+88,830
| +4,960% | +$410K | ﹤0.01% | 2802 |
|
|
2024
Q1 | $14.6K | Hold |
1,791
| – | – | ﹤0.01% | 3808 |
|
|
2023
Q4 | $10.1K | Hold |
1,791
| – | – | ﹤0.01% | 3860 |
|
|
2023
Q3 | $3.33K | Sell |
1,791
-2,256
| -56% | -$4.2K | ﹤0.01% | 4041 |
|
|
2023
Q2 | $11.1K | Sell |
4,047
-63,041
| -94% | -$173K | ﹤0.01% | 3919 |
|
|
2023
Q1 | $211K | Buy |
67,088
+2,786
| +4% | +$8.76K | ﹤0.01% | 2729 |
|
|
2022
Q4 | $379K | Buy |
64,302
+269
| +0.4% | +$1.59K | ﹤0.01% | 2595 |
|
|
2022
Q3 | $562K | Buy |
64,033
+3,981
| +7% | +$34.9K | ﹤0.01% | 2441 |
|
|
2022
Q2 | $453K | Buy |
60,052
+19,353
| +48% | +$146K | ﹤0.01% | 2545 |
|
|
2022
Q1 | $987K | Buy |
40,699
+2,423
| +6% | +$58.8K | ﹤0.01% | 2136 |
|
|
2021
Q4 | $1.23M | Buy |
38,276
+81
| +0.2% | +$2.61K | ﹤0.01% | 2123 |
|
|
2021
Q3 | $1.71M | Buy |
38,195
+3,630
| +11% | +$162K | ﹤0.01% | 1993 |
|
|
2021
Q2 | $1.31M | Buy |
34,565
+24,284
| +236% | +$919K | ﹤0.01% | 2131 |
|
|
2021
Q1 | $380K | Buy |
10,281
+1,689
| +20% | +$62.4K | ﹤0.01% | 2614 |
|
|
2020
Q4 | $285K | Buy |
+8,592
| New | +$285K | ﹤0.01% | 2691 |
|